河南省抗HIV治疗效果及耐药变异分析  

Efficacy of anti-HIV treatment and drug-resistance mutations in Henan province,China

作　　者：崔为国[1] 胡清海[2] 李宏[1] 朱新朋[1] 孙国清[1] 田随安[1] 刘春华[1] 曹广华[3] 范二军 张旻[2] 

机构地区：[1]河南省疾病预防控制中心艾滋病实验室,郑州450016 [2]中国医科大学附属第一医院艾滋病研究所 [3]河南省上蔡县疾病预防控制中心 [4]河南省尉氏县疾病预防控制中心

出　　处：《中国公共卫生》2009年第10期1218-1219,共2页Chinese Journal of Public Health

基　　金：卫生部艾滋病防治研究项目资助(WA2006-02)

摘　　要：目的研究河南省人类免疫缺陷病毒/艾滋病(HIV/AIDS)患者应用高效抗逆转录病毒治疗后治疗效果及耐药变异产生情况。方法对采用2种治疗方案的河南省HIV/AIDS患者进行病毒载量、CD4+T淋巴细胞数、耐药变异基因型监测。结果2种治疗方案都在部分HIV/AIDS患者身上取得病毒载量抑制和提升CD4+T淋巴细胞数效果,但用药后均有耐药变异发生,2005年D4T/ddI/NVP、AZT/ddI/NVP高度耐药相关突变率分别为19.7%,16.2%;2006年分别为19.4%,19.5%。结论河南省HIV/AIDS患者应用高效抗逆转录病毒治疗(HAART)治疗基本上取得了预期的疗效,但在应用逆转录酶抑制剂后有耐药变异发生,且多为交叉耐药、多药耐药。所以应用逆转录酶抑制剂时要加强耐药监测,规范管理,及时调查用药以节省有限的药物资源并防止耐药株的产生。Objective To study the virological and immunological effcacy of HAART among Chinese HIV/AIDS patients and its influence of drug resistance mutations. Methods Viral load, CD4^＋ T lymphocytes count and drug resistance genotype were detected in patients after two regimens treatment. Results Undetectable viral load level and CD4^＋ T lymphocytes maintenance were achieved among a part of HIV/AIDS patients, but drug resistance mutations happened during the two regimens. High drug resistance mutation rates of D4T/ddI/NVP, AZT/ddI/NVP were 19.7%, 16. 2% in 2005, and 19.4%, 19. 5% in 2006. Conclusion Expected efficacy was achieved in Chinese HIV/AIDS patients. But the high prevalence of drug resistance mutations against reverse transcriptase inhibitors, crossing drug resistance, and multi-drug resistance suggest that more attention should be paid to the drug resistance mutation detection, treatment standardization.

关 键 词：人类免疫缺陷病毒/艾滋病(HIV/AIDS) 病毒载量 CD4 耐药变异 

分 类 号：R512.91[医药卫生—内科学]